Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Recro Pharma logo

About Recro Pharma Stock (NASDAQ:REPH)

Key Stats

Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
The Great AI-Energy Collision
The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector.
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
See More Headlines

REPH Stock Analysis - Frequently Asked Questions

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
3/01/2022
Today
11/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
Employees
185
Year Founded
N/A

Profitability

Net Income
$-11,370,000.00
Pretax Margin
-15.09%

Debt

Sales & Book Value

Annual Sales
$75.36 million
Book Value
$0.90 per share

Miscellaneous

Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:REPH) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners